NEFL, neurofilament light, 4747

N. diseases: 247; N. variants: 26
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE Plasma NFL shows particular promise as an accessible biomarker with relevance to cognition in MCI. 31700989 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 GeneticVariation disease BEFREE To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-β (Aβ42) modified these associations. 30419087 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 AlteredExpression disease BEFREE The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. 31009028 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 AlteredExpression disease BEFREE There was a stepwise increase in CSF NFL levels between control participants (median [range] score, 536 [398-777] pg/mL), participants with MCI (831 [526-1075] pg/mL), and those with Alzheimer disease (951 [758-1261] pg/mL), indicating that NFL levels increase with increasing cognitive impairment. 30508027 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE An integrated model included clinical features, hippocampus volume, and plasma Aβ42 and NFL and had the highest accuracy for detecting aMCI patients (accuracy, 74.2%). 31145586 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE Among Alzheimer's Disease Neuroimaging Initiative participants with normal cognition (n = 117), mild cognitive impairment (n = 190), and Alzheimer's disease (n = 95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis. 31381510 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE CSF TMAO is higher in individuals with MCI and AD dementia compared to cognitively-unimpaired individuals, and elevated CSF TMAO is associated with biomarkers of AD pathology (phosphorylated tau and phosphorylated tau/Aβ<sub>42</sub>) and neuronal degeneration (total tau and neurofilament light chain protein). 30579367 2018
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 GeneticVariation disease BEFREE In contrast, the minor allele (G) of rs640476 near GABRB2 was associated with lower plasma NFL at suggestive levels (P = 6.71 × 10<sup>- 6</sup>) in a dose-dependent effect in all diagnostic groups except the MCI group. 29747637 2018
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE We produced two monoclonal antibodies (NfL21 and NfL23) directed against the NfL core domain, and developed a novel sandwich ELISA method that we evaluated in patients with: 1) inflammatory demyelinating diseases (IDD; n = 97), including multiple sclerosis (MS; n = 59), clinically isolated syndrome (CIS; n = 32), and radiologically isolated syndrome (RIS; n = 6); 2) Alzheimer's disease (AD; n = 72), including mild cognitive impairment due to AD (MCI-AD, n = 36) and probable AD dementia (AD-dem; n = 36); 3) Parkinson's disease (PD; n = 30); and 4) other neurological noninflammatory and non-neurodegenerative diseases (OND; n = 30). 29370869 2018
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 AlteredExpression disease BEFREE Cerebrospinal fluid NFL levels were quantified in nonprimarily neurodegenerative neurological and psychiatric diseases (n = 122), mild cognitive impairment (n = 48), Alzheimer's disease (n = 108), dementia with Lewy bodies/Parkinson's disease dementia (n = 53), vascular dementia (n = 46), frontotemporal dementia (n = 41), sporadic Creutzfeldt-Jakob disease (sCJD, n = 132), and genetic prion diseases (n = 182). 29391125 2018
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE An NFL × diagnosis interaction (excluding early mild cognitive impairment) on WM microstructure (p-values < 0.05) was detected, with associations strongest among MCI. 30036759 2018
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE We suggest that factors previously shown to be important for brain degeneration in mild cognitive impairment may also impact changes in normal aging, demonstrating that NFL is likely to indicate AD-independent, age-expected neurodegeneration. 27794264 2017
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. 28346578 2017
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.100 Biomarker disease BEFREE A combination of the biomarkers Abeta(42), T-tau, P-tau(181) and NF-L has the potential to improve the clinical separation of MCI-SVD patients from stable MCI and MCI-AD patients. 19864909 2009